Vistra Corp. Stock Sheds 6.3%, Underperforms Peers
Dow Jones2026/10/08 20:33This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Vistra Corp. slipped 6.3% to $156.14 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.1% to 51,231.64 and the S&P 500 Index falling 0.5% to 7,765.36. The stock's fall snapped a five-day winning streak. Vistra Corp. closed 28.1% short of its 52-week high of $217.10, which the company achieved on October 16th. The stock underperformed when compared to some of its peers, as NextEra Energy Inc. rose 0.4% to $77.37, Southern Co. rose 0.8% to $86.15, and American Electric Power Co. Inc. rose 0.20% to $122.32. Trading volume totaled 11.3 million, compared to the 50-day average of 5.4 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 08, 2026 16:33 ET (20:33 GMT)
This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Vistra Corp. slipped 6.3% to $156.14 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.1% to 51,231.64 and the S&P 500 Index falling 0.5% to 7,765.36.
The stock's fall snapped a five-day winning streak.
Vistra Corp. closed 28.1% short of its 52-week high of $217.10, which the company achieved on October 16th.
The stock underperformed when compared to some of its peers, as NextEra Energy Inc. rose 0.4% to $77.37, Southern Co. rose 0.8% to $86.15, and American Electric Power Co. Inc. rose 0.20% to $122.32.
Trading volume totaled 11.3 million, compared to the 50-day average of 5.4 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 08, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
MSCI adopts index exclusion rules that could oust Strategy
No scientific evidence but viral on social media: “Bodybuilding miracle drug” peptide products deregulation file sent to the White House for review, Hims&Hers (HIMS.US) surged 6% in one day.
The temporary admission policy for peptides has been submitted to the White House for review, and compounding pharmacies are expected to receive approval to produce BPC-157 and other substances; HIMS closed up 6% on Thursday.
AiCoin丨10.16 Snapshot: PPI Exceeds Expectations, Russia Bans P2P, US Stock ETF Net Outflow
Crypto prices
More
